Titre : Tumeurs de l'abdomen

Tumeurs de l'abdomen : Questions médicales fréquentes

Termes MeSH sélectionnés :

Programmed Cell Death 1 Receptor
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Tumeurs de l'abdomen : Questions médicales les plus fréquentes", "headline": "Tumeurs de l'abdomen : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Tumeurs de l'abdomen : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-09", "dateModified": "2025-04-04", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Tumeurs de l'abdomen" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Tumeurs par siège", "url": "https://questionsmedicales.fr/mesh/D009371", "about": { "@type": "MedicalCondition", "name": "Tumeurs par siège", "code": { "@type": "MedicalCode", "code": "D009371", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.588" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Tumeurs du rétropéritoine", "alternateName": "Retroperitoneal Neoplasms", "url": "https://questionsmedicales.fr/mesh/D012186", "about": { "@type": "MedicalCondition", "name": "Tumeurs du rétropéritoine", "code": { "@type": "MedicalCode", "code": "D012186", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.588.033.731" } } }, { "@type": "MedicalWebPage", "name": "Nodule de Soeur Marie-Joseph", "alternateName": "Sister Mary Joseph's Nodule", "url": "https://questionsmedicales.fr/mesh/D058288", "about": { "@type": "MedicalCondition", "name": "Nodule de Soeur Marie-Joseph", "code": { "@type": "MedicalCode", "code": "D058288", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C04.588.033.740" } } } ], "about": { "@type": "MedicalCondition", "name": "Tumeurs de l'abdomen", "alternateName": "Abdominal Neoplasms", "code": { "@type": "MedicalCode", "code": "D000008", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Robert Stoehr", "url": "https://questionsmedicales.fr/author/Robert%20Stoehr", "affiliation": { "@type": "Organization", "name": "Institute of Pathology, University Hospital Erlangen (UKER), Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany." } }, { "@type": "Person", "name": "Abbas Agaimy", "url": "https://questionsmedicales.fr/author/Abbas%20Agaimy", "affiliation": { "@type": "Organization", "name": "Institute of Pathology, University Hospital Erlangen (UKER), Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany. abbas.agaimy@uk-erlangen.de." } }, { "@type": "Person", "name": "Naseema Gangat", "url": "https://questionsmedicales.fr/author/Naseema%20Gangat", "affiliation": { "@type": "Organization", "name": "Mayo Clinic, Rochester, MN, USA." } }, { "@type": "Person", "name": "Paul H Sugarbaker", "url": "https://questionsmedicales.fr/author/Paul%20H%20Sugarbaker", "affiliation": { "@type": "Organization", "name": "Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, Washington, District of Columbia, USA." } }, { "@type": "Person", "name": "David Chang", "url": "https://questionsmedicales.fr/author/David%20Chang", "affiliation": { "@type": "Organization", "name": "Westat, Rockville, Maryland, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.", "datePublished": "2023-01-24", "url": "https://questionsmedicales.fr/article/36645031", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/exd.14750" } }, { "@type": "ScholarlyArticle", "name": "MicroRNAs Targeting Programmed Cell Death Protein 1 (PD-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis.", "datePublished": "2022-12-24", "url": "https://questionsmedicales.fr/article/36640056", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.18502/ijaai.v21i6.11524" } }, { "@type": "ScholarlyArticle", "name": "Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy.", "datePublished": "2023-04-21", "url": "https://questionsmedicales.fr/article/37153623", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1138145" } }, { "@type": "ScholarlyArticle", "name": "A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.", "datePublished": "2022-09-06", "url": "https://questionsmedicales.fr/article/35758515", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2340/actadv.v102.1062" } }, { "@type": "ScholarlyArticle", "name": "Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.", "datePublished": "2022-11-25", "url": "https://questionsmedicales.fr/article/36442821", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.actbio.2022.11.043" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Tumeurs", "item": "https://questionsmedicales.fr/mesh/D009369" }, { "@type": "ListItem", "position": 3, "name": "Tumeurs par siège", "item": "https://questionsmedicales.fr/mesh/D009371" }, { "@type": "ListItem", "position": 4, "name": "Tumeurs de l'abdomen", "item": "https://questionsmedicales.fr/mesh/D000008" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Tumeurs de l'abdomen - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Tumeurs de l'abdomen", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Tumeurs de l'abdomen", "description": "Comment diagnostiquer une tumeur abdominale ?\nQuels tests sanguins sont utiles ?\nQuels symptômes indiquent une tumeur abdominale ?\nQuelle imagerie est la plus précise ?\nQuand faire une échographie abdominale ?", "url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Tumeurs de l'abdomen", "description": "Quels sont les symptômes courants des tumeurs abdominales ?\nLa jaunisse est-elle un symptôme ?\nPeut-on avoir des symptômes sans tumeur visible ?\nLes tumeurs abdominales causent-elles des vomissements ?\nComment la fatigue est-elle liée aux tumeurs ?", "url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Tumeurs de l'abdomen", "description": "Peut-on prévenir les tumeurs abdominales ?\nLe tabagisme augmente-t-il le risque ?\nL'alcool est-il un facteur de risque ?\nLes infections peuvent-elles causer des tumeurs ?\nLe surpoids est-il un risque ?", "url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Tumeurs de l'abdomen", "description": "Quels sont les traitements des tumeurs abdominales ?\nQuand est la chirurgie nécessaire ?\nLa chimiothérapie est-elle efficace ?\nQuels effets secondaires des traitements ?\nLa radiothérapie est-elle utilisée ?", "url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Tumeurs de l'abdomen", "description": "Quelles complications peuvent survenir ?\nLes tumeurs peuvent-elles causer des douleurs chroniques ?\nComment les tumeurs affectent-elles la digestion ?\nLes tumeurs abdominales peuvent-elles causer des infections ?\nQuelles sont les conséquences d'une métastase ?", "url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Tumeurs de l'abdomen", "description": "Quels sont les principaux facteurs de risque ?\nLes antécédents médicaux influencent-ils le risque ?\nL'exposition à des produits chimiques est-elle un risque ?\nLe stress a-t-il un impact sur le risque ?\nLes maladies génétiques augmentent-elles le risque ?", "url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une tumeur abdominale ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par imagerie (IRM, scanner) et biopsie." } }, { "@type": "Question", "name": "Quels tests sanguins sont utiles ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs tumoraux comme l'AFP et le CA 19-9 peuvent aider au diagnostic." } }, { "@type": "Question", "name": "Quels symptômes indiquent une tumeur abdominale ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Douleurs abdominales, perte de poids, nausées et changements d'appétit." } }, { "@type": "Question", "name": "Quelle imagerie est la plus précise ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'IRM est souvent plus précise pour visualiser les tissus mous." } }, { "@type": "Question", "name": "Quand faire une échographie abdominale ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'échographie est utile pour évaluer des masses abdominales suspectes." } }, { "@type": "Question", "name": "Quels sont les symptômes courants des tumeurs abdominales ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleurs, ballonnements, nausées et perte d'appétit." } }, { "@type": "Question", "name": "La jaunisse est-elle un symptôme ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la jaunisse peut indiquer une tumeur au foie ou des voies biliaires." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans tumeur visible ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes peuvent apparaître même sans tumeur détectable." } }, { "@type": "Question", "name": "Les tumeurs abdominales causent-elles des vomissements ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les vomissements peuvent survenir en raison de l'obstruction intestinale." } }, { "@type": "Question", "name": "Comment la fatigue est-elle liée aux tumeurs ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "La fatigue peut résulter de la maladie, des traitements ou de l'anémie." } }, { "@type": "Question", "name": "Peut-on prévenir les tumeurs abdominales ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mesures comme une alimentation saine et l'exercice peuvent réduire le risque." } }, { "@type": "Question", "name": "Le tabagisme augmente-t-il le risque ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque pour plusieurs types de tumeurs abdominales." } }, { "@type": "Question", "name": "L'alcool est-il un facteur de risque ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une consommation excessive d'alcool peut augmenter le risque de tumeurs hépatiques." } }, { "@type": "Question", "name": "Les infections peuvent-elles causer des tumeurs ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections, comme l'hépatite B, peuvent augmenter le risque de cancer du foie." } }, { "@type": "Question", "name": "Le surpoids est-il un risque ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'obésité est associée à un risque accru de plusieurs tumeurs abdominales." } }, { "@type": "Question", "name": "Quels sont les traitements des tumeurs abdominales ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent chirurgie, chimiothérapie et radiothérapie." } }, { "@type": "Question", "name": "Quand est la chirurgie nécessaire ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La chirurgie est souvent nécessaire pour retirer la tumeur et les tissus environnants." } }, { "@type": "Question", "name": "La chimiothérapie est-elle efficace ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut réduire la taille des tumeurs et prévenir les récidives." } }, { "@type": "Question", "name": "Quels effets secondaires des traitements ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, fatigue, et perte de cheveux." } }, { "@type": "Question", "name": "La radiothérapie est-elle utilisée ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est utilisée pour traiter certaines tumeurs abdominales localisées." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la métastase, l'obstruction intestinale et l'hémorragie." } }, { "@type": "Question", "name": "Les tumeurs peuvent-elles causer des douleurs chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tumeurs peuvent provoquer des douleurs chroniques en raison de leur taille ou de leur emplacement." } }, { "@type": "Question", "name": "Comment les tumeurs affectent-elles la digestion ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent provoquer des obstructions, entraînant des problèmes digestifs." } }, { "@type": "Question", "name": "Les tumeurs abdominales peuvent-elles causer des infections ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tumeurs peuvent affaiblir le système immunitaire, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quelles sont les conséquences d'une métastase ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les métastases peuvent affecter d'autres organes, compliquant le traitement et le pronostic." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, le tabagisme, l'alcool et des antécédents familiaux." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies comme la colite peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'exposition à des produits chimiques est-elle un risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certains produits chimiques peut augmenter le risque de cancer abdominal." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut influencer la santé globale, mais son lien direct est moins clair." } }, { "@type": "Question", "name": "Les maladies génétiques augmentent-elles le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies génétiques comme le syndrome de Lynch augmentent le risque." } } ] } ] }

Sources (10000 au total)

Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.

Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand programmed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, includi...

Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis.

Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC) by the European... Post hoc analysis of the Chinese JUPITER-06 study focusing on efficacy stratified by PD-L1 tumor proportion score (TPS; using JS311 antibody) was conducted. Electronic databases were searched to ident... The post hoc analysis of JUPITER-06 showed more prominent clinical benefit with PD-1 antibody plus chemotherapy than with chemotherapy alone in both the high and low PD-L1-expressing subgroups. Five r... This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of pred...

Association between programmed death-1 pathway and major depression.

Major depression (MD) may be associated with inflammation and immunity. PD-1 (programmed death-1), PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2) are among the inhibitory immu... During a period of 2 years, patients with MD and healthy controls were recruited from a medical centre in this study. The diagnosis of MD was established according to the DSM-5 criteria. The severity ... A total of 54 patients with MD and 38 healthy controls were recruited. According to the analyses, there is a significantly higher PD-L2 level in MD than in healthy controls and lower PD-1 level after ... It was found that PD-1 pathway might play an important role in MD. We need a large sample to prove these results in the future....

Programmed cell death protein 1 is a marker for neoadjuvant chemotherapy response in triple-negative breast cancer.

Tumor-infiltrating lymphocytes are detectable in up to 75% of triple-negative breast cancer. The composition of these infiltrates may influence prognosis and is not known regarding regulatory or effec... This was a retrospective observational study. Clinical and pathological data from 38 triple-negative breast cancer patients treated with neoadjuvant chemotherapy at the University Hospital (HUCFF/UFRJ... Statistically significant changes in stromal tumor-infiltrating lymphocyte categories were observed before and post-neoadjuvant chemotherapy, with 32% of intermediate cases becoming high. The correlat... In this study, we observed that chemotherapy significantly increases stromal tumor-infiltrating lymphocytes, CD8 T cells, as well as CD8/FoxP3 ratio. Most importantly, programmed cell death protein 1 ...